Trials / Completed
CompletedNCT02661958
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 726 (actual)
- Sponsor
- Sol-Gel Technologies, Ltd. · Industry
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the superiority in efficacy and assess safety and tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active components or the vehicle for the treatment of acne.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S6G5T-3 | once a day topical cream |
| DRUG | S6G5T-1 | once a day topical cream |
| DRUG | S6G5T-5 | once a day topical cream |
| DRUG | S6G5T-6 | once a day topical cream |
| DRUG | S6G5T-7 | once a day topical cream |
| DRUG | S6G5T-8 | once a day topical cream |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-10-01
- Completion
- 2017-10-01
- First posted
- 2016-01-25
- Last updated
- 2019-09-19
Locations
34 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02661958. Inclusion in this directory is not an endorsement.